Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301

Reuters2026/08/06 22:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evommune outlined two Phase 2 programs in chronic inflammatory diseases, led by EVO756 in atopic dermatitis and migraine.
EVO756 Phase 2b atopic dermatitis top-line data expected in September 2026; Phase 3 planned in 1H 2027.
EVO756 Phase 2b migraine trial initiated in July 2026; top-line data expected in 2027.
EVO301 posted positive Phase 2a atopic dermatitis data in February 2026; Phase 2b planned in 2027 with subcutaneous formulation, data expected in 2028.
Cash and investments of about $287 million as of June 30, 2026; runway anticipated through 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301

You may also like

Crypto prices